A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia

Trial Profile

A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Torticollis
  • Focus Registrational; Therapeutic Use
  • Sponsors Ipsen
  • Most Recent Events

    • 14 Mar 2017 According to an Ipsen media release, health Canada has approved Dysport (abobotulinumtoxinA) in the treatment of adult patients with Cervical Dystonia; the approval was based on data from this and extension study.
    • 21 Apr 2016 Primary endpoint [Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)] has been met, according to Results presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top